ALPMY Stock UPDATES Astellas Pharma Inc (ALPMY) 14.2500 09/10/2014

New Post Public Reply Private Reply Replies (0) Message Board

Sep 10, 2014 at 10:19 PM

Astellas Pharma Inc (ALPMY) 14.2500 $ALPMY

Astellas' Antifungal Under FDA Review, Response by Mar 2015 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 4:50PM CDT
Astellas (ALPMY) and partner Basilea's new drug application for isavuconazole is under FDA review for invasive aspergillosis and invasive mucormycosis.

Astellas-Basilea's Isavuconazole Accepted for EU Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 4:30PM CDT
Astellas Pharma, Inc. (ALPMY) and Basilea's isavuconazole has been accepted for review in the EU for the treatment of invasive aspergillosis and mucormycosis.

AVEO Pharmaceuticals Posts Narrower-than-Expected Q2 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 13, 8:30AM CDT
AVEO Pharmaceuticals reported a second-quarter 2014 loss of 35 cents per share.

Medivation Jumps on Q2 Earnings Beat, Outlook Encourages - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 11, 11:10AM CDT
Medivation Inc. (MDVN) posted earnings of 60 cents per share.

Astellas Up on Pipeline Update, Oncology in Focus (revised) - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 3:07PM CDT
Astellas Pharma, Inc. (ALPMY) provided a comprehensive overview of its initiatives towards innovation, research and development and its corporate strategy.

Astellas' Isavuconazole Gets QIDP for Invasive Candidiasis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 17, 4:50PM CDT
Astellas Pharma, Inc.'s (ALPMY) isavuconazole received Qualified Infectious Disease Product (QIDP) designation from the FDA for treating invasive candidiasis.

Astellas Up on Pipeline Update, Oncology in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 16, 2:03PM CDT
Astellas Pharma, Inc.'s (ALPMY) shares gained 2.5% following the company's update on its pipeline and corporate strategy late last week.

Astellas Seeks FDA Nod for Fungal Infection Treatment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 4:30PM CDT
Astellas Pharma, Inc. (ALPMY) has filed an NDA with the FDA for isavuconazole for the treatment of invasive aspergillosis and mucormycosis.

ARIAD Candidate in Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 5:10PM CDT
ARIAD started phase II pivotal study on AP26113 for non-small cell lung cancer (NSCLC) in patients who had previously been treated with Pfizer's Xalkori (crizotinib).

AstraZeneca's Forxiga Approved in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 25, 3:45PM CDT
AstraZeneca announced that its type II diabetes drug, Forxiga, has been approved by the Japanese Ministry of Health, Labour and Welfare.

Japan Approves Medivation/Astellas' Xtandi - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 25, 12:50PM CDT
Prostate cancer treatment, Xtandi, which is already approved in more than 35 countries is now approved in Japan.

AVEO Regains AV-203 Rights from Biogen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 5:10PM CDT
AVEO Oncology (AVEO) recently announced that it has regained worldwide rights of candidate AV-203 from Biogen Idec (BIIB).

Medivation, Inc: Fast Growing Drugs That May Become Blockbusters
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 21, 1:30PM CDT
Blockbuster status -- the gold medal term awarded to therapies racking up sales of more than $1 billion per year -- is the Holy Grail for drug developers. Arguably, it's the chance to discover blockbusters that fuels industry R&D spend and...

Medivation-Astellas Seek Xtandi Label Expansion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 3:20PM CDT
The companies are looking to get Xtandi approved for the chemo-naive patient population.

AVEO Q4 Loss Narrower than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 8:10AM CDT
AVEO Pharmaceuticals reported a fourth quarter 2013 loss of 32 cents per share.

Was Medivation's Quarter a Disaster?
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 03, 5:30PM CST
Medivation's sell-off last week reflects investor disappointment in guidance for sales of Xtandi, a prostate cancer drug prescribed to patients who fail to respond to chemotherapy. Sales of Xtandi jumped double digit percentages...

Medivation Swings to Earnings in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 8:30AM CST
Xtandi's approval in the pre-chemo setting would boost sales significantly.

Biotech Stock Roundup: Regeneron's Eylea Impresses, Gilead Files for Next HCV Drug - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 19, 8:27AM CST
The Medicines Co. was also in the news with an FDA advisory panel refusing to back the company's antiplatelet agent, Cangrelor.

Primco Files Preliminary Form 14c to Increase Authorized Shares
PR Newswire - Tue Feb 18, 11:30PM CST
Primco Management Inc. (OTCQB: PMCM), a fully integrated multi-media entertainment and real estate development company today announced that the Company has filed Form 14c, as required by the Securities and Exchange Commission, informing shareholders of an increase in the authorized to 25 billion common shares as a reserve requirement for possible future conversion issuances, in accordance with contractual obligations to convertible debt holders based on the recent low stock price of $0.0001. The increase will further allow Primco to have sufficient shares available for equity funding, and/or for potential acquisitions which the Board of Directors may determine is in the best interest of the shareholders.

AVEO/Astellas Terminate Agreement - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 18, 3:30PM CST
AVEO Pharma and Astellas announced their decision to terminate their agreement for the development and commercialization of tivozanib.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Endava Faces Class Action: Investor Reactions and Next Steps

Trouble at Endava: Leadership Shakeup and Financial Concerns So, here's the kicker—Endava's got itself into one mighty mess worth chewing over with your morning coffee. When your top brass drops like flies, and you're fumbling your financials, investors start sweating bullets. On October 28, 2026, Endava plc (NYSE: DAVA) confesses to some serious accounting missteps....

Revolutionary Sports Ball Backpack: A Game Changer?

Backpacks Reinvented by a Clever Mom Ever been caught in the whirlwind of juggling kids, sports gear, and school supplies? Well, one stay-at-home mom from Poway, California found herself in just such a predicament. She turned this everyday chaos into a creative solution by designing a unique Sports Ball Backpack. The idea came to her while managing a toddler, a newborn,...

Duke Energy's Cooling Tips Amid Florida Cold Front

Weather Whiplash in Florida Prompts Energy Tips Florida's residents are in for a gust of chilly air as a cold front sweeps across the state, sending temperatures plummeting from the balmy 80s to brisk 30s and 40s in northern pockets. Central Florida ain't missing out on the chill either, expecting to dip a good dozen degrees below its usual seasonal warmth. Heads up,...

Shorenstein Expands in Dallas: Strategic Play or Risk?

Shorenstein's recent acquisition of International Plaza 3 isn't just about adding another high-rise to their portfolio; it's a stake in the ground, a doubling down on the Dallas real estate market. With its aim sharply set on the Lower Tollway submarket, Shorenstein is showing confidence, but the big question remains—are they spot on or walking the razor's edge?...

Surprising Week on Wall Street: Chips Drive Gains

A Wild Week in Wall Street Well, folks, what a week it’s been on Wall Street. The indexes danced the cha-cha, making gains despite closing Friday on a lower note. Despite the retreat, we've got ourselves a week where the major indexes closed higher than the previous Friday. It's not the usual story, but who ever thought stocks played by the rules? The Nasdaq Composite...

LEOTEK's AI Tech Shaping Smarter Cities at COP31

AI-Powered Evolution in Urban Infrastructure Hang on to your hats, folks, 'cause LEOTEK is turning heads at COP31 with its AI-driven transformation of urban landscapes. As cities stretch at the seams to keep up with modern challenges, LEOTEK's got more than a few tricks up its sleeve with its trademark blend of traffic system intelligence and energy management prowess....

Matthew Callstrom Named CEO: Mayo Clinic's Next Era

Leadership Change at Mayo Clinic: A Turning Point The Mayo Clinic, a titan in healthcare lands, is on the cusp of a major leadership switch-up. As the trustees hand the reins to Dr. Matthew R. Callstrom, they're banking on a rich blend of experience and visionary thinking to steer their ship. We're looking at what this change might spell for Mayo's storied mission. Who is...

YYForce Expands in UAE with Key Hospitality Wins

Unveiling YYForce's Middle East Strategy Smack in the middle of an aggressive Middle Eastern expansion, YYForce (NASDAQ: YFOR) is making waves with some new headline-grabbing contracts in the UAE. This ain't just a side hustle—it's big time. They're planting their flag across the luxury hospitality sector like they're going for a moon landing. The recent announcement...

SPOC Energy's Hiring Push Signals Growth Surge

A Growing Workforce for a Growing Demand Here we are, smack dab in a bustling week of business news, and among it, SPOC Energy is ramping up its workforce across Alabama. Now, SPOC isn't any run-of-the-mill operation; this Birmingham-based manufacturer messes around with advanced power conversion systems and motor-control automation—a mouthful, sure, but critical stuff...

Winterproofing Your Home: Simple Tips to Save Money

Winter Is Coming: Time to Prep Your Home When it’s cold enough to freeze a dog's nose, the last place you want a surprise is in your own cozy corner of the world. Quality Heating, Cooling, Plumbing & Electric, the whiz-kids from Glenpool, Oklahoma, are out with some pointers for keeping your house peachy all through winter's tests. We’re talking ways to dodge frozen...